Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland.
Africa Centres for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia.
Nat Med. 2024 Sep;30(9):2432-2443. doi: 10.1038/s41591-024-03218-w. Epub 2024 Sep 3.
The pipeline of new antibiotics is insufficient to keep pace with the growing global burden of drug-resistant infections. Substantial economic challenges discourage private investment in antibiotic research and development (R&D), with a decline in the number of companies and researchers working in the field. Compounding these issues, many countries (from low income to high income) face a growing crisis of antibiotic shortages and inequitable access to existing and emerging treatments. This has led to an increasing role for public and philanthropic funding in supporting antibiotic R&D via the creation of nonprofit public-private partnerships, including Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the Global Antibiotic Research and Development Partnership (GARDP), industry support for the AMR Action Fund, and pilot schemes to evaluate and reimburse antibiotics in innovative ways. Now is the time to raise the urgency, ambition and commitments of the world's leaders to fully support the antibiotic R&D ecosystem, incentivizing all sectors to conduct public health-driven antibiotic R&D and make effective antibiotics accessible to all who need them.
新抗生素的研发速度赶不上全球耐药感染负担的日益加重。巨大的经济挑战阻碍了私人投资抗生素研发（R&D），从事该领域的公司和研究人员数量不断减少。此外，许多国家（从低收入到高收入国家）都面临着抗生素短缺和现有及新兴治疗方法获取不平等的日益严重的危机。这导致公共和慈善资金通过创建非营利公私合作伙伴关系，包括抗菌药物耐药性生物制药加速器（CARB-X）和全球抗菌药物研发伙伴关系（GARDP），为支持抗生素研发发挥了越来越大的作用，为抗微生物药物行动基金提供了行业支持，并制定了试点方案，以创新方式评估和报销抗生素。现在是时候提高世界各国领导人的紧迫性、雄心和承诺，以全力支持抗生素研发生态系统，激励所有部门开展以公共卫生为导向的抗生素研发，使所有需要抗生素的人都能获得有效抗生素。
